SJSTOCKSHARK Thursday, 08/15/19 12:26:05 PM Re: None Post # of 6201 Conference call update: BPTH in first Q raised 21 million in cash of which only 17 million is left. The cash burn rate will increase to 2 million per quarter. Only 8 1/2 quarters of cash rremains. The science continues to look good with only one more patient needed for Dasatinib/Prexigebersen safety trial to be completed. The results will be released probably in the 4th Q. The triple safety study adding Venetoclax will then begin for another 6 patients. 19 evaluable patients will again be needed for the triple study. To me the real potential is BP-1003 which targets the stat 3 protein. Patient dosing will not begin for this drug until the second half of 2020. PN needs to raise more cash. He should sell 1 million shares of stock now and raise 11 million This would give the company 3 1/2 years to bring a drug to market or sell the drug rights.